3-(2-methoxyphenyl)-2'-trifluoromethylpropiophenone, 97.0%, 1g

Ethyl 6-cyanopicolinate, 95.0%, 10g

5-((3aS,8aS)-2,2-Dimethyl-4,4,8,8-tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepin-6-yl)-5H-dibenzo[b,f]azepine, 97%, 100mg

BOC-(R)-3-AMINO-4-(3,4-DIFLUOROPHENYL)-BUTYRIC ACID, 97.0%, 1g

(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, 98%, 25g

3-(Pyridin-3-yl)aniline, 95.0%, 5g

2,4-Dimethylpyrimidine-5-carboxylic acid, 97.0%, 1g

1-(2,6-DIFLUORO-4-NITROPHENYL)PIPERIDIN-4-ONE, 95.0%, 250mg

Óxido de vanadio(IV) en polvo 99,5% -100 malla 10 g

Inhibidor de tripsina, 25 mg

1-azepanesulfonyl chloride, 95.0%, 1g

4-Chloro-5-fluoropyridine-3-carboxylic Acid, 98+%, 1g

N-(tert-Butoxycarbonyl)-L-norvaline>95.0%(HPLC)1g